Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
52.04
+3.13 (6.40%)
At close: Jun 12, 2026, 4:00 PM EDT
51.65
-0.39 (-0.75%)
After-hours: Jun 12, 2026, 4:56 PM EDT
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $127.20M in the quarter ending March 31, 2026, with 55.63% growth. This brings the company's revenue in the last twelve months to $536.20M, up 96.03% year-over-year. In the year 2025, Travere Therapeutics had annual revenue of $490.73M with 110.45% growth.
Revenue (ttm)
$536.20M
Revenue Growth
+96.03%
P/S Ratio
9.03
Revenue / Employee
$1,078,863
Employees
497
Market Cap
4.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 490.73M | 257.55M | 110.45% |
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
| Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | 175.34M | 11.09M | 6.75% |
| Dec 31, 2018 | 164.25M | 9.31M | 6.01% |
| Dec 31, 2017 | 154.94M | 21.35M | 15.98% |
| Dec 31, 2016 | 133.59M | 33.70M | 33.74% |
| Dec 31, 2015 | 99.89M | 71.69M | 254.19% |
| Dec 31, 2014 | 28.20M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 907.29M |
| Ligand Pharmaceuticals | 274.48M |
| Tango Therapeutics | 56.99M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 5.07M |
| CRISPR Therapeutics AG | 4.10M |
| Dianthus Therapeutics | 1.34M |
TVTX News
- 2 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 days ago - Travere Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Travere Therapeutics says Filspari generally well tolerated in Phase 3 study - TheFly
- 9 days ago - Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - Business Wire
- 10 days ago - Travere Therapeutics price target raised to $62 from $59 at Citi - TheFly
- 10 days ago - Travere Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 11 days ago - Travere Therapeutics price target raised to $67 from $57 at H.C. Wainwright - TheFly
- 11 days ago - Travere Therapeutics Transcript: Investor update - Transcripts